Brain Tumor Center
The Lenox Hill Brain Tumor Center offers comprehensive care for brain and spinal cord tumors in adults and children. Our experts utilize state-of-the-art surgical and nonsurgical techniques to treat tumors. In addition to our continuous pursuit of evidence-based medicine, the center emphasizes treatment of the whole patient and the crucial role of family in a patient's care.
Lenox Hill Neurosurgery is the only department in New York City to receive the 2018 Healthgrades Cranial Neurosurgery Excellence Award for superior outcomes in cranial neurosurgery. Additionally, Lenox Hill is one of only two hospitals in Manhattan to achieve an Excellent 30 day survival and Above Average patient safety score in the 2018 U.S. News & World Report rankings of the best hospitals for Neurology and Neurosurgery.
Our center works closely with the Laboratory for Brain Tumor Biology and Therapy, and the Brain Tumor Biotech Center at the Feinstein Institute for Medical Research to offer cutting-edge diagnosis and treatment.
Our neurosurgeons utilize surgical and nonsurgical techniques to treat tumors and use state-of-the-art equipment such as image guided systems for precise surgical navigation and radiotherapy for painless, nonsurgical treatment.
Our multidisciplinary team specializes in treating all types of brain tumors, including:
Primary and metastatic brain tumors
Skull base tumors
Spinal cord tumors
Lenox Hill is the only hospital in NYC to receive the 2018 Healthgrades Cranial Neurosurgery Excellence Award.
Lenox Hill is the first hospital in the country to acquire a videomicroscope, a device that offers astounding magnified, high-resolution, 3D images—helping surgeons perform and collaborate on delicate brain and spine operations.
Our patient and caregiver-focused group meets on the fourth Monday of each month from 5pm to 6:30pm. Sessions end with Yinyasa yoga; please bring a mat if you have one. Light refreshments will be served. RSVP to Sherese Fralin, NP, at [email protected] or (212) 434-4772.
Brain Tumor Biotech Summit
Held at Lenox Hill Hospital, the summit brought together the nation’s top cancer specialists and the investment community to promote innovative new therapies for brain tumors.
The research arm of the Lenox Hill Brain Tumor Center is the Laboratory for Brain Tumor Biology and Therapy at the Feinstein Institute for Medical Research. The lab draws experts from multiple disciplines to participate in leading-edge research into brain and spinal cord tumors.
Our neuroscientists use discoveries in the lab to create new treatments for patients through a robust clinical trial program. Our doctors run the Brain Tumor Biotech Center at the Feinstein Institute, which is the only biotech center in the world dedicated to accelerating treatments for patients with brain tumors.
Our patients have access to clinical studies offering novel, state-of-the-art therapies developed by our own physicians, as well as those that are done in collaboration with other sites. Ongoing trials include the following:
Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/neu Positive Breast Cancer
PI: John Boockvar, MD
The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into your artery for the treatment of your brain metastasis(es) from HER2/neu positive breast cancer. This study will try to determine the best tolerated single dosage of trastuzumab administered into arteries by gradually increasing the dosage given to participants as the study progresses. Early participants will receive a dosage of 1 mg/kg. As more participants enroll into the study, this single dosage will be increased at designated levels up to 8 mg/kg, if it’s determined to be safe to increase. Trastuzumab is a type of antibody, which is a protein used by the body’s immune system to fight against pathogens such as bacteria and viruses. This antibody binds to cell receptors known as the HER2/neu tyrosine kinase receptor. These receptors are expressed in certain cancer subtypes such as breast cancer. By blocking signaling through this HER2/neu receptor, trastuzumab can slow down or stop the over-expression of the HER2/neu protein. Over-expression of HER2/neu has been shown to play a role in the development and progression of certain types of breast cancer. Therefore, by slowing down or stopping the expression of HER2/neu, we hope to slow down or stop the growth of your metastasis(es) and increase the responsiveness to therapy.
Using genomic analysis to guide individualized treatment in glioblastoma multiforme (GBM). The purpose of this study is to assess whether the use of genomics can help identify patient specific treatment choices in cancer. In order to test this, we plan to use genomic sequencing technology to identify patient specific mutations in glioblastoma multiforme (GBM) as compared to normal cells of the blood from the same patient to identify mutations. Further analysis will identify potential treatment targets and whether there are any drugs that could be used for these particular mutations. Follow up clinical data will be assessed to see if this individualized method of choosing treatment options can improve clinical outcomes in patients with GBM.
Phase I Trial of Super-Selective Intra-Arterial Infusion of Cetuximab (ERBITUX) with or without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
PI: John Boockvar, MD
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC). Cetuximab has recently emerged as a promising biological agent in the management of HNSCC. It is an epidermal growth factor receptor (EGFR) inhibitor which increases the radiosensitivity of tumors to radiotherapy (RT), and has been proven to be effective. A large body of evidence supports the theoretical attractiveness of intra-arterial chemotherapy, related to the first pass of the drug through the tumor bed and to the possibility of increasing the doses of the chemotherapeutic agent, thus minimizing systemic toxic side effects. Theoretically, a higher dose of Cetuximab saturating the tumor tissue’s EGFR receptor will increase its responsiveness with or without concurrent radiation therapy.
This phase I clinical research trial will test the hypothesis that Temozolomide can be safely used by Superselective Intraarterial Cerebral Infusion (SIACI) up to a dose of 250mg/m2 to ultimately enhance survival of patients with newly diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma. Data suggests that Temozolomide is active in newly diagnosed GBM but that current response rates can be improved, and toxicity with systemic delivery could be avoided with selective delivery techniques such as SIACI.
This phase I/II clinical research trial will test the hypothesis that repeated dosing of of intra-arterial Bevacizumab at 15 mg/kg can be safely administered to enhance survival of subjects with newly diagnosed Glioblastoma multiforme while they receive standard of care. We expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for newly diagnosed malignant glioma, and may alter the way these drugs are delivered to our patients in the future.
A recent study showed that IV Bevacizumab (Avastin) treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both, in some patients with vestibular schwannoma who were at risk for complete hearing loss or brainstem compression from growing VS. Because of these promising results in preliminary studies, and because of our significant experience with the safety of intraarterial chemotherapy, this novel study will offer a safe treatment for patients with VS. This is the only center in the United States where this trial is being offered.
Superselective Intraarterial Cerebral Infusion (SIACI) is a technique that can effectively increase the concentration of drug delivered to the brain while sparing the body of systemic side effects. One currently used drug called, Cetuximab (Erbitux) has been shown to be active in human brain tumors but its actual CNS penetration is unknown. This phase I clinical research trial will test the hypothesis that Cetuximab can be safely used by direct intraarterial infusion up to a dose of 250mg/m2 to ultimately enhance survival of patients with relapsed/refractory GBM/AA. This study will allow investigators to determine the the toxicity profile and maximum tolerated dose (MTD) of SIACI Cetuximab. The investigators expect that this study will provide important information regarding the utility of SIACI Cetuximab therapy for malignant gliomas, and may alter the way these drugs are delivered to the investigators patients in the near future.
Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD
This phase I/II clinical research trial will test the hypothesis that repeated direct intraarterial infusion Bevacizumab (15mg/kg) can be safely administered to enhance survival of patients with relapsed/refractory Glioblastoma Multiforme and Anaplastic Astrocytoma. The current standard of care for recurring GBM is for patients to receive Bevacizumab (Avastin) intravenously (IV) at 10mg/kg every two weeks until their tumor grows more than 25%. This study will help investigators determine if IV therapy with Bevacizumab should be combined with repeated selected intra-arterial Bevacizumab to improve progression free and overall survival.
Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) Plus Carboplatin (Paraplatin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD
This phase I/II clinical research trial is an extension of our Phase I IA Avastin trial in that we seek to test the hypothesis that repeated dosing of intraarterial Bevacizumab is safe and effective in the treatment of recurrent malignant glioma. Additionally we will investigate whether the combination with Carboplatin will further improve the treatment response. We will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival.
Phase I/II Trial Of Repeated Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD
This phase I/II clinical research trial will test the hypothesis that repeated dosing of intra-arterial Cetuximab is safe and effective in the treatment of recurrent malignant glioma. We will also determine if IV therapy with Cetuximab should be combined with repeated selected intra-arterial Cetuximab to improve progression free and overall survival.
Our staff is dedicated to educating the next generation of medical professionals at our renowned medical school.
We’re empowering imagination and supporting pioneering discovery to transform our field and create a better tomorrow.
This is an interactive hub for scientists, clinicians and biotech companies in the neuro-oncology space to join forces and accelerate the delivery of novel drugs to patients living with brain tumors.